SCHOTT Pharma Forecast, price target & analysts
SCHOTT Pharma Target price 2026 - Analyst rating & recommendation
SCHOTT Pharma Classifications & Recommendation
SCHOTT Pharma Price Target
| Target Price | €25.50 |
| Price | €25.00 |
| Potential |
2.00%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target SCHOTT Pharma 2027 .
The average SCHOTT Pharma target price is €25.50.
This is
2.00%
register free of charge
€28.35
13.40%
register free of charge
€13.13
47.48%
register free of charge
|
|
| A rating was issued by 19 analysts: 15 Analysts recommend SCHOTT Pharma to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the SCHOTT Pharma stock has an average upside potential 2027 of
2.00%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion € | 0.99 | 1.06 |
| 3.04% | 7.08% | |
| EBITDA Margin | 27.01% | 27.27% |
| 1.13% | 0.98% | |
| Net Margin | 14.85% | 14.24% |
| 5.05% | 4.11% |
15 Analysts have issued a sales forecast SCHOTT Pharma 2026 . The average SCHOTT Pharma sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an SCHOTT Pharma EBITDA forecast 2026. The average SCHOTT Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 SCHOTT Pharma Analysts have issued a net profit forecast 2026. The average SCHOTT Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.97 | 1.00 |
| 2.02% | 3.09% | |
| P/E | 24.69 | |
| EV/Sales | 3.55 |
15 Analysts have issued a SCHOTT Pharma forecast for earnings per share. The average SCHOTT Pharma EPS is
This results in the following potential growth metrics and future valuations:
Current SCHOTT Pharma Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| BNP PARIBAS |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Aug 27 2026 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 14 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
BNP PARIBAS:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Aug 27 2026 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 14 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
